|
- 积分
- 85
- 威望
- 85
- 包包
- 41
|
1Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study
1 x8 s/ K4 q3 i1 V0 X9 L8 l) ~http://circheartfailure.ahajournals.org/content/6/4/711.long
! V' T' s6 V; \$ L8 t( u2，Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy: Results From the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) http://circheartfailure.ahajournals.org/content/7/1/51.long
) T0 ^7 c$ o2 w3，Incidence, Predictors and Outcomes Related to Hypo and Hyperkalemia in Severe Heart Failure Patients Treated with a Mineralocorticoid Receptor Antagonist., W9 s5 M8 O" v Y% }
http://www-ncbi-nlm-nih-gov.ezpr ... Receptor+Antagonist9 n; U1 M% f4 `* X1 O6 [* M+ Z
|
|
发表于 2014-5-28 23:30
发表于 2014-5-29 09:31
